Outcomes of prolotherapy in chondromalacia patella patients: improvements in pain level and function

Ross A Hauser, Ingrid Schaefer Sprague, Ross A Hauser, Ingrid Schaefer Sprague

Abstract

We retrospectively evaluated the effectiveness of prolotherapy in resolving pain, stiffness, and crepitus, and improving physical activity in consecutive chondromalacia patients from February 2008 to September 2009. Sixty-nine knees that received prolotherapy in 61 patients (33 female and 36 male) who were 18-82 years old (average, 47.2 years) were enrolled. Patients received 24 prolotherapy injections (15% dextrose, 0.1% procaine, and 10% sarapin) with a total of 40 cc in the anterior knee. At least 6 weeks after their last prolotherapy session, patients provided self-evaluation of knee pain upon rest, activities of daily living (ADL) and exercise, range of motion (ROM), stiffness, and crepitus. Symptom severity, sustained improvement of symptoms, number of pain pills needed, and patient satisfaction before treatment and improvement after treatment were recorded. Following prolotherapy, patients experienced statistically significant decreases in pain at rest, during ADL, and exercise. Stiffness and crepitus decreased after prolotherapy, and ROM increased. Patients reported improved walking ability and exercise ability after prolotherapy. For daily pain level, ROM, daily stiffness, crepitus, and walking and exercise ability, sustained improvement of over 75% was reported by 85% of patients. Fewer patients required pain medication. No side effects of prolotherapy were noted. The average length of time from last prolotherapy session was 14.7 months (range, 6 months to 8 years). Only 3 of 16 knees were still recommended for surgery after prolotherapy. Prolotherapy ameliorates chondromalacia patella symptoms and improves physical ability. Patients experience long-term improvement without requiring pain medications. Prolotherapy should be considered a first-line, conservative therapy for chondromalacia patella.

Keywords: cartilage; chondromalacia patella; knee; osteoarthritis; pain; prolotherapy.

References

    1. Wheaton MT, Jensen N. The ligament injury connection to osteoarthritis. Journal of Prolotherapy. 2010;2(1):294–304.
    1. Hauser RA, Cukla JJ. Standard clinical x-ray studies document cartilage regeneration in five degenerated knees after prolotherapy. Journal of Prolotherapy. 2009;1:22–8.
    1. Kim S. Changes in surgical loads and economic burden of hip and knee replacements in the US: 1997–2004. Arthritis Rheum. 2008;59(4):481–8.
    1. Hackett GS, Hemwall GA, Montgomery GA. Ligament and Tendon Relaxation Treated by Prolotherapy. 5th edition. Oak Park (IL): Gustav A. Hemwall; 1993.
    1. Hauser RA. The regeneration of articular cartilage with prolotherapy. Journal of Prolotherapy. 2009;1(1):39–44.
    1. Hauser RA. The acceleration of articular cartilage degeneration in osteoarthritis by nonsteroidal anti-inflammatory drugs. Journal of Prolotherapy. 2010;2(1):305–22.
    1. Palmoski MJ, Colyer RA, Brandt KD. Marked suppression by salicylate of the augmented proteoglycan synthesis in osteoarthritis cartilage. Arthritis Rheum. 1980;23(1):83–91.
    1. Palmoski MJ, Brandt KD. Effects of some nonsteroidal anti-inflammatory drugs on proteoglycan metabolism and organization in canine articular cartilage. Arthritis Rheum. 1980;23(9):1010–20.
    1. Brandt KD, Slowman-Kovacs S. Nonsteroidal antiinflammatory drugs in the treatment of osteoarthritis. Clin Orthop Related Res. 1986;213:84–91.
    1. Palmoski MJ, Brandt KD. Relationship between matrix proteoglycan content and the effect of salicylate and indomethacin on articular cartilage. Arthritis Rheum. 1983;26(4):528–31.
    1. McKenzie LS, Horsburgh BA, Ghosh P, Taylor TK. Letter: Osteoarthrosis: uncertain rationale for anti-inflammatory drug therapy. Lancet. 1976;1(7965):908–9.
    1. Dekel S, Falconer J, Francis MJ. The effect of anti-inflammatory drugs on glycosaminoglycan sulphation in pig cartilage. Prostaglandins Med. 1980;4(3):133–40.
    1. Mitrovic D, McCall E, Front P, Aprile F, Darmon N, Dray F. Anti-inflammatory drugs, prostanoid and proteoglycan production by cultured bovine articular chondrocytes. Prostaglandins. 1984;28(3):417–34.
    1. Serni U, Mannoni A, Benucci M. Is there preliminary in-vivo evidence for an influence of nonsteroidal anti-inflammatory drugs on progression in osteoarthritis? Part II-evidence from animal models. Osteoarthritis Cartilage. 1999;7(3):351–2.
    1. Kalbhen DA. The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage of osteoarthrosis and its counteraction by a biological GAG-peptide complex (Rumalon) Z Rheumatol. 1982;41(5):202–11.
    1. Chang JK, Wu SC, Wang GJ, Ho ML. Effects of non-steroidal anti-inflammatory drugs on cell proliferation and death in cultured epiphyseal-articular chondrocytes of fetal rats. Toxicology. 2006;228(2–3):111–23.
    1. Matsuda K, Nakamura S, Matsushita T. Celecoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritis rat joints. Rheumatol Int. 2006;26(11):991–5.
    1. Schwartz Z, Gilley RM, Sylvia VL, Dean DD, Boyan BD. The effect of prostaglandin E2 on costochondral chondrocytes differentiation is mediated by clinic adenosine 3′, 5′-monophosphate and protein kinase C. Endocrinology. 1998;139(4):1825–34.
    1. O’Keefe RJ, Crabb ID, Puzas JE, Rosier RN. Influence of prostaglandins on DNA and matrix synthesis in growth plate chondrocytes. J Bone Miner Res. 1992;7(4):397–404.
    1. Miyamoto M, Ito H, Mukai S, et al. Simultaneous stimulation of EP2 and EP4 is essential to the effect of prostaglandin E2 in chondrocytes differentiation. Osteoarthritis Cartilage. 2003;11(9):644–52.
    1. Clark CA, Schwarz EM, Zhang X, et al. Differential regulation of EP receptor during chondrogenesis and chondrocytes maturation. Biochem Biophy Res Commun. 2005;328(3):764–76.
    1. Brochhausen C, Neuland P, Kirkpatrick CJ, Nüsing RM, Klaus G. Cyclooxygenases and prostaglandin E2 in growth plate chondrocytes in vitro and in situ–Prostaglandin E2 dependent proliferation on growth plate chondrocytes. Arthritis Res Ther. 2006;8(3):1–21.
    1. Maroudas A, Evans H, Almeida L. Cartilage of the hip joint. Topographical variation of glycosaminoglycan content in normal and fibrillated tissue. Ann Rheumatologic Dis. 1973;32(1):1–9.
    1. Mankin HJ, Lippiello L. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. J Bone Joint Surg Am. 1970;52(3):424–31.
    1. McKenzie LS, Horsburgh BA, Ghosh P, Taylor TK. Effect of anti-inflammatory drugs on sulphated glycosaminoglycan synthesis in aged human articular cartilage. Ann Rheumatologic Dis. 1976;35(6):487–97.
    1. Dingle JT. Prostaglandins in human cartilage metabolism. J Lipid Mediators. 1993;6(1–3):303–12.
    1. Reijman M, Bierma-Zeinstra SM, Pols HA, Koes BW, Stricker BH, Hazes JM. Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis Rheum. 2005;52(10):3137–42.
    1. Lane NE, Wallace DJ. All About Osteoarthritis: The Definitive Resource for Arthritis Patients and Their Families. Oxford University Press; Oxford, England: 2002. p. 19.
    1. Andriacchi TP, Lang PL, Alexander EJ, Hurwitz DE. Methods for evaluating the progression of osteoarthritis. J Rehab Res Dev. 2000;37(2):163–70.
    1. Schnitzer T, Popovich JM, Andersson GB, Andriacchi TP. Effect of piroxicam on gait in patients with osteoarthritis of the knee. Arthritis Rheum. 1990;36(9):1207–13.
    1. Hauser RA. The deterioration of articular cartilage in osteoarthritis by corticosteroid injections. Journal of Prolotherapy. 2009;2:107–23.
    1. Scott J, Huskisson EC. Accuracy of subjective measurements made with or without previous scores: an important source of error in serial measurement of subjective states. Ann Rheum Dis. 1979;38(6):558–9.
    1. Hauser RA, Hauser MA. A retrospective study on dextrose prolotherapy for unresolved knee pain at an outpatient charity clinic in rural Illinois. Journal of Prolotherapy. 2009;1:11–21.
    1. Lennard T. Pain Procedures in Clinical Practice. Second edition. Philadelphia: Hanley and Belfus, Inc; 2000.
    1. Lennard T. Physiatric Procedures in Clinical Practice. Philadelphia: Hanley and Belfus, Inc; 1995.
    1. Hauser R, Hauser M. Prolo Your Pain Away! Second edition. Oak Park, IL: Beulah Land Press; 2004.
    1. Dorman T. Prolotherapy in the Lumbar Spine and Pelvis. Philadelphia: Hanley and Belfus, Inc; 1995.
    1. Hackett GS. Ligament and Tendon Relaxation Treated by Prolotherapy. Fifth edition. Oak Park, IL: Gustav A. Hemwall; 1992.
    1. Reeves KD. Prolotherapy: present and future applications in soft tissue pain and disability. Physical Medicine & Rehabilitation Clinics of North America. 1995;6:917–26.
    1. Ongley M, Dorman TA, Bjorn CE, Lundgren D, Klein RG. Ligament instability of knees: a new approach to treatment. Manual Medicine. 1988;3:152–4.
    1. Hackett GS. Prolotherapy in whiplash and low back pain. Postgrad Med. 1960;27:214–9.
    1. Kayfetz D. Occipital-cervical (whiplash) injuries treated by prolotherapy. Med Trial Tech. 1963:9–29.
    1. Reeves K, Hassanein K. Randomized, prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. Altern Ther Health Med. 2000;6(2):68–74. 77–80.
    1. Ongley M. Ligament instability of knees: A new approach to treatment. Manual Medicine. 1988;3:152–4.
    1. Fullerton BD. High-resolution ultrasound and magnetic resonance imaging to document tissue repair after prolotherapy: a report of 3 cases. Arch Phys Med Rehabil. 2008;89(2):377–85.
    1. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–62.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner